Page 140 - 南京医科大学自然版

第45卷第10期
·1508 · 南 京 医 科 大 学 学 报 2025年10月

表2 靶向CAF的不同治疗策略的介绍
Table 2 Introduction to different therapeutic strategies targeting CAF
Molecular
Target Therapeutic strategy subtypes of Mechanism/Description Research stage
breast cancer
FAP αFAP⁃PE38 TNBC Depleting FAP+ stromal cells inhibits tumor growth and me⁃ Preclinical study
tastasis
FAP targeted DNA TNBC Reduce spontaneous lung metastases through immune re⁃ Preclinical study
vaccine+Azithromycin sponses
FAP targets CAR⁃T+ TNBC FAP targeted therapy combined with CAR⁃T cell therapy en⁃ Preclinical study
PD⁃1 inhibitor hances T cell infiltration，inhibits tumor metastasis and pro⁃
longs survival
FAP⁃IL2v HER2positive Regulate immune responses and improve drug resistance in Preclinical study
HER2⁃positive breast cancer
FAP⁃IL2v alone/+ Undistinguis To evaluate the safety，pharmacokinetics and anti⁃tumor ac⁃ Phase I clinical trial
trastuzumab/+ hed tivity of FAP⁃IL2v alone or in combination with trastuzumab （NCT02627274）
cetuximab or cetuximab in the treatment of breast cancer

TGF⁃β Fresolimumab+ Undistinguis To test the efficacy and safety of Fresolimumab combined Phase Ⅱ clinical trial
radiotherapy hed with radiotherapy in the treatment of metastatic breast can⁃ （NCT01401062）
cer
Galunisertib+ TNBC Limit tumor metastasis by reducing angiogenesis Preclinical study
Escherichia coli strain
Galunisertib+PD⁃L1 TNBC Regulate T cell activity and inhibit tumor growth Preclinical study
inhibitor
Galunisertib+ TNBC To determine the side effects and optimal dose of Galunisert⁃ Phase Ⅰ clinical trial
paclitaxel ib+ paclitaxel combination therapy for metastatic TNBC （NCT02672475）
Bintrafusp alfa TNBC Neutralizing TGF⁃β while blocking PD⁃L1，it inhibits tumor Preclinical study
growth and lung metastasis
Bintrafusp alfa+ TNBC with To evaluate the safe dose，intracranial progression time and Phase Ⅰ/Ⅱ clinical
MAPKK1/2inhibitor brain overall survival time of Bintrafusp alfa+MEK1/2 inhibitor in trial NCT04789668）
metastasis the treatment of TNBC with brain metastases
Bintrafusp alfa+ Luminal To determine the side effects and optimal dose of Bintrafusp Phase Ⅰ clinical trial
radiotherapy alfa combined with radiotherapy in the treatment of patients （NCT03524170）
with metastatic Luminal type

CXCR4 AMD3100 HER2 By blocking CXCR4，tumor growth in HER2⁃positive breast Preclinical study
positive， cancer models resistant to Herceptin or docetaxel can be in⁃
TNBC hibited，but in TNBC models，it promotes tumor metastasis

AMD3100+ TNBC AMD3100 can enhance the inhibitory effect of radiotherapy Preclinical study
radiotherapy on the proliferation and migration of tumor cells

HA PEGPH20+Eribulin HER2 To evaluate the safety and efficacy of PEGPH20 combined Phase Ⅰb/Ⅱ clinical
negative with aribrin in the treatment of HER2⁃negative breast cancer trial（NCT02753595）

TNC Knockdown TNC+anti HER2 Down⁃regulation of TNC combined with anti⁃PD⁃L1 therapy Preclinical study
⁃PD⁃L1 positive inhibits the metastasis of HER2⁃positive breast cancer by
enhancing the immune cell response to tumor infiltration